As spring hits its peak in Paris, the global interventional cardiology community is preparing to descend upon the Palais des Congrès de Paris for EuroPCR 2026. Running from May 19 to May 22, this year’s iteration of the world’s leading interventional medicine course promises to be a transformative event. With a theme centered on the mantra, "Education Saves Lives: Preventing and Solving Complications," the conference aims to bridge the gap between groundbreaking research and real-world clinical application.
The scale of the event is, as always, immense. Attendees can expect over 500 sessions, 800 hours of programming, and the expertise of 3,000 faculty members and presenters. The scientific output is record-breaking: 1,984 clinical cases, 1,129 abstracts, and a staggering 166 late-breaking clinical trials. For practitioners in the field, this represents an unparalleled opportunity to refine techniques and stay at the cutting edge of cardiovascular care.
The Foundation of Excellence: Pre-Course Initiatives
Before the main sessions begin on Tuesday, May 19, the program offers a robust pre-course agenda on Monday, May 18. This day is strategically designed to cater to the future of the field and the innovators shaping it.
The PCR Fellows Course remains a cornerstone of the pre-meeting programming, specifically curated for early-career interventionalists. Recognizing that the future of medicine rests on the training of the next generation, this track provides intensive mentorship and technical guidance. Concurrently, Innovators Day will bring together key stakeholders—industry leaders, venture capitalists, and clinicians—to discuss the pipeline of future medical devices. Additionally, a dedicated one-day program will focus on the role of coronary physiology in clinical decision-making, providing a deep dive into the diagnostic tools that allow for more precise, patient-centered care.
Scientific Highlights: The "Major" Trials
Course directors Thomas Cuisset, MD, PhD, Nicolas Dumonteil, MD, and Nieves Gonzalo, MD, have curated a scientific program that addresses the most contentious and significant issues in the current landscape. Three "major" late-breaking trials, slated for presentation in Theatre Bleu on Wednesday, May 20, at 9:45 AM, are expected to dominate the conversation:
- Revascularization in Aortic Stenosis: A patient-level meta-analysis investigating the necessity of revascularization for patients with concomitant coronary artery disease and aortic stenosis scheduled for Transcatheter Aortic Valve Implantation (TAVI).
- Left Main CAD Outcomes: A long-term follow-up study comparing Coronary Artery Bypass Grafting (CABG) against Percutaneous Coronary Intervention (PCI) for left main disease. Given the historical volatility surrounding the EXCEL trial data, this study is expected to provide much-needed clarity on mortality outcomes, potentially influencing future clinical guidelines.
- LAAO vs. DOACs: An age-stratified comparison of Left Atrial Appendage Occlusion (LAAO) versus Direct Oral Anticoagulants (DOACs) for atrial fibrillation patients. This study arrives at a critical juncture, following the mixed results of the CHAMPION-AF and CLOSURE-AF trials, and will test the limits of noninferiority in real-world practice.
Chronology of Clinical Data: A Four-Day Deep Dive
The scientific narrative of EuroPCR 2026 is distributed across a rigorous four-day schedule.
Tuesday, May 19: Focus on Complexity and New Tech
Following the morning opening, the noon hour kicks off the first of many hotline sessions. The focus will be on the management of calcified lesions—a persistent challenge for interventionalists. This will be followed by a session dedicated to emerging coronary devices, including the latest in thinner-strut bioresorbable scaffolds and the "unlocking" Bioadaptor technology. By 3:00 PM, the focus shifts toward the tricuspid valve, where new procedural outcomes will be unveiled, alongside a session on optimizing pharmacology for coronary artery disease.
Wednesday, May 20: The Heavy Hitters
Wednesday is arguably the most dense day of the conference. Beyond the "major" studies, the agenda features seven additional hotline sessions. Early morning attendees will explore innovative strategies for Acute Coronary Syndromes (ACS), with a particular focus on drug-coated balloons (DCBs) and intravascular lithotripsy.
Mid-morning will see a focus on transcatheter mitral interventions and structural heart devices. The 11:15 AM slot is highly anticipated, featuring data from the SMART trial (3-year outcomes), the LANDMARK trial (2-year follow-up), and NOTION-2. These trials collectively represent the effort to standardize and improve TAVI outcomes across varying patient risk profiles. Afternoon sessions will further investigate the efficacy of DCBs, particularly in small-vessel disease and de novo lesions.
Thursday, May 21: TAVI and High-Risk Intervention
The penultimate day shifts focus toward procedural strategies for TAVI, with morning sessions dedicated to optimizing clinical practice. At 11:00 AM, the conversation moves to high-risk revascularization. This session will include a randomized comparison of Left Ventricular (LV) unloading during complex PCI, as well as data from the PROTECT-EU registry regarding the use of LV support in high-risk patients. The day concludes with sessions on advanced imaging-guided interventions and the assessment of microvascular disease using physiology.
Friday, May 22: Closing the Loop
The final day features a targeted session on LAAO and pulmonary embolism (PE). Of particular note is a meta-analysis comparing mechanical thrombectomy against catheter-directed thrombolysis for PE—a debate that remains at the forefront of venous thromboembolism care.
Live Cases: Learning in Real-Time
EuroPCR’s signature "Live Cases" remain a fundamental educational tool, providing a window into the techniques of world-class operators. Eight clinical sites, including the Cleveland Clinic (London), the Leipzig Heart Centre, and the University Hospital Basel, will broadcast live procedures.
The 17 cases selected for this year cover a broad spectrum of interventional cardiology:
- Transcatheter mitral valve replacement (TMVR)
- TAVI and mitral valve-in-valve procedures
- Physiology-guided PCI
- Management of Chronic Total Occlusions (CTO)
- Revascularization in complex, heavily calcified coronary anatomy
By observing these procedures in real-time, attendees gain insights into decision-making, complication management, and technical nuance that cannot be replicated in a slide presentation.
Implications for the Future of Cardiology
The 2026 program is not merely a collection of data; it is an indicator of the industry’s trajectory. The increased focus on simulation-based learning and the "Skills Lab" for calcification suggests a pivot toward hands-on proficiency. Furthermore, the partnership with TCT for the Innovation Hub—with a dedicated focus on Artificial Intelligence (AI) in cardiology—signals that the next decade of interventional medicine will be defined by the integration of algorithmic intelligence with human dexterity.
For the clinician, the implications are clear: the bar for what constitutes "best practice" is rising. Whether it is the move toward physiological assessment over angiography, or the refinement of valve technology for younger, lower-risk patients, the data presented at EuroPCR 2026 will undoubtedly serve as the foundation for the next generation of clinical guidelines.
A Note to Attendees
For those attending, the pace will be relentless. With over 1,000 abstracts to review and a social calendar that includes both professional networking and the occasional sunrise run, the week promises to be as exhausting as it is enlightening. TCTMD’s team, including myself, Yael L. Maxwell, and L.A. McKeown, will be on the ground providing comprehensive coverage. We invite you to reach out if you have a story to tell or a perspective to share. As the industry gathers in Paris, the goal remains the same as the conference theme: to save lives through education, precision, and the relentless pursuit of better patient outcomes.
For the full program and further details on registration, please visit the official EuroPCR website.
